Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2-Reference-Cited by-同舟云学术

Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2

Published:2023-06 Issue: Volume:214 Page:105606
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Li Yihua,Wang Kun,Sun Hongmin,Wu Shuo,Wang Huiqiang,Shi Yuanyuan,Li Xingxing,Yan Haiyan,Yang Ge,Wu Mengyuan,Li Yihong,Ding Xiaotian,Si Shuyi,Jiang Jiandong,Du Yu^ORCID,Li Yuhuan,Hong Bin^ORCID

Funder

CAMS Innovation Fund for Medical Sciences

National Natural Science Foundation of China

Chinese Academy of Meteorological Sciences

Natural Science Foundation of Beijing Municipality

National Key Research and Development Program of China

National Key Research and Development Program of China Stem Cell and Translational Research

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference53 articles.

1. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders;Al-Horani;Med. Res. Rev.,2014

2. Thrombin inhibition by argatroban: potential therapeutic benefits in COVID-19;Aliter;Cardiovasc. Drugs Ther.,2021

3. Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L;Ashhurst;J. Med. Chem.,2022

4. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors;Böttcher-Friebertshäuser;J. Virol.,2010

5. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases;Carmona;Biochemistry,1996

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs;Journal of Medicinal Chemistry;2024-07-05

2. Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization;European Journal of Medicinal Chemistry;2024-02

3. Repurposing and discovery of transmembrane serine protease 2 (TMPRSS2) inhibitors as prophylactic therapies for new coronavirus disease 2019 (COVID-19);PHARMAZIE;2023